Sanofi (NASDAQ:SNY) Upgraded to Strong-Buy by StockNews.com

Sanofi (NASDAQ:SNY) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.

Other equities research analysts also recently issued reports about the stock. Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Down 1.1 %

Shares of NASDAQ SNY traded down $0.63 during midday trading on Friday, reaching $57.63. 1,942,893 shares of the stock were exchanged, compared to its average volume of 2,060,200. The stock has a market capitalization of $145.96 billion, a P/E ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a 50 day simple moving average of $54.34 and a 200 day simple moving average of $50.48. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.95 earnings per share. As a group, equities analysts expect that Sanofi will post 4.25 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. POM Investment Strategies LLC purchased a new stake in Sanofi during the 2nd quarter worth about $25,000. Frazier Financial Advisors LLC purchased a new stake in shares of Sanofi in the 4th quarter valued at about $28,000. Register Financial Advisors LLC acquired a new stake in shares of Sanofi in the 1st quarter valued at about $29,000. Larson Financial Group LLC grew its stake in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in Sanofi during the 4th quarter worth approximately $31,000. 10.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.